Future Forecasts of Rheumatoid Arthritis Therapeutics Market Overall and Across Various Sub-Segments till 2025 is Provided in the Report
Clinical diagnoses of rheumatoid arthritis have seen a turnaround with the advent of multiple antibody assays such as antibodies to citrullinated protein/peptide antigens (ACPAs). This helps in better diagnosis and management of RA with much improved overall diagnostic sensitivity. The market is also witnessing a shift towards combination therapy which manifests results.
The report “Global Rheumatoid Arthritis Therapeutics Market (By Type - Biologics, Biosimilars, NSAIDs, Analgesics, DMARDs & Glucocorticoids; By Region - North America, Europe & Asia Pacific) Market Outlook 2025” provides an in-depth analysis of global rheumatoid arthritis therapeutics market across therapeutics segments such as Pharmaceuticals and Biopharmaceuticals. Market outlook for rheumatoid arthritis therapeutics market overall as well as across various sub-segments has been provided for the period 2018-24. Regional analysis is done across major markets in North America, Europe and the Asia Pacific.
The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market-specific growth opportunities in the global rheumatoid arthritis therapeutics market.
The report has been segmented as follows:
- North America - The US
- Asia Pacific
- Abbvie Inc.
- Amgen Inc.
- F. Hoffman-La Roche AG
- Johnson & Johnson
- Pfizer Inc.
Table of Contents
1. Executive Summary2. Research Methodology
3.3 Types of RA
5.2 Market Share Analysis
5.2.1 Market Share by Molecule Type
5.2.2 Market Share by Distribution Channel
5.2.3 Market Share by Region
6.1.1 Market Sizing (Actual & Forecasted)
126.96.36.199 Market Sizing (Actual & Forecasted)
188.8.131.52 Market Share by Drug Type
184.108.40.206 Market Sizing (Actual & Forecasted)
6.2.1 Market Sizing (Actual & Forecasted)
220.127.116.11 Market Sizing (Actual & Forecasted)
7.1.1 Market Sizing (Actual & Forecasted)
7.1.2 Market Share by Molecule Type
7.2 Asia Pacific
7.2.1 Market Sizing (Actual & Forecasted)
7.3.1 Market Sizing (Actual & Forecasted)
8.1.1 Preference for Combination Therapies
8.1.2 Growing Demand for Janus Kinase (JAK) inhibitors
8.1.3 Use of Anti-ACPAs for Clinical Diagnosis
8.1.4 FDA Approval of Auto-Injector for RA
8.2 Growth Drivers
8.2.1 Prevalence of Rheumatoid Arthritis
8.2.2 Increasing Geriatric Population
8.2.3 Growing Patient Awareness
8.3.1 Entry of Biosimilars
8.3.2 High Cost of Treatment
8.3.3 Issues related to Insurance & Reimbursement
10.2 Amgen Inc.
10.3 F. Hoffmann-La Roche AG
10.4 Johnson & Johnson
10.5 Pfizer Inc.
Rheumatoid Arthritis (RA) is a chronic inflammatory disorder that affects the joints of the body, causing inflammation. Over a period of time, this inflammation can lead to bone erosion and joint deformity. It is an autoimmune disease in which immune system mistakenly attacks body’s own tissues including linings of joints. Although this disease is not age-specific, it is most commonly seen in women aged over 40 years. One of the most probable causes of RA is genetic inheritance. Early diagnosis of RA is difficult as it readily resembles other forms of inflammatory arthritis. A blood test which identifies biomarkers such as Rheumatoid factor (RF) antibody serves as an important identifier of the disease.
Treatment paradigm of autoimmune diseases such as rheumatoid arthritis begins with a non-steroidal anti-inflammatory drug (NSAID) and disease-modifying anti-rheumatic drug (DMARD). Patients with unsatisfactory response to these are administered with Biologics. The growth of global rheumatoid arthritis therapeutics market is spurred by the prevalence of rheumatoid arthritis, increasing geriatric population and growing patient awareness about rheumatoid arthritis. However, the market faces several challenges due to the entry of Biosimilars, the high cost of treatment and issues related to insufficient insurance coverage and reimbursement.
The report “Global Rheumatoid Arthritis Therapeutics Market (By Type - Biologics, Biosimilars, NSAIDs, Analgesics, DMARDs & Glucocorticoids; By Region - North America, Europe & Asia Pacific) Market Outlook 2025” provides in-depth analysis of the current scenario, detailed market outlook of the global rheumatoid arthritis therapeutics market with coverage on major therapeutic segments such as Biologics and Biosimilars in Biopharmaceuticals drug type and NSAIDs, Analgesics and DMARDs in Pharmaceuticals. Future forecasts of rheumatoid arthritis therapeutics market overall and across various sub-segments till 2025 is provided in the report. Furthermore, major industry players have been prudently analysed in the competitive landscape section of the report in order to provide key comparative insights.
Major industry players operating in the global rheumatoid arthritis therapeutics market include Abbvie Inc., Amgen Inc., F. Hoffman-La Roche AG, Johnson & Johnson, Pfizer Inc., among others. These players are profiled herein based on attributes such as business overview, product segments, and financial analysis. It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics.
This information will be helpful in evaluating opportunities in the global rheumatoid arthritis therapeutics market.
- Abbvie Inc
- Amgen Inc
- F. Hoffman - La Roche AG
- Johnson & Johnson
- Pfizer Inc